Search Results

Tenecteplase Shows Benefit for Intermediate-Risk Patients With Pulmonary Embolism

March 11, 2013—Findings from the PEITHO (Pulmonary Embolism Thrombolysis) study, which tested the addition of a thrombolytic drug, tenecteplase, to standard treatment with heparin, were presented at the 62nd annual scientific session of the American College of Cardiology (ACC) in San Francisco, California.

Boehringer Ingelheim's Pradaxa Approved in EU for DVT and PE Treatment

June 6, 2014—Boehringer Ingelheim announced that the company’s Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

HI-PEITHO: Boston Scientific’s Ekos System Superior to Anticoagulation Alone in Acute Intermediate-Risk PE

March 28, 2026—Boston Scientific Corporation announced that the HI-PEITHO global randomized clinical trial evaluating the use of the Ekos endovascular system in patients with intermediate-risk pulmonary embolism (PE) met the composite primary endpoint.

Boston Scientific’s EkoSonic System Studied With Anticoagulation in HI-PEITHO Trial

August 4, 2021—Boston Scientific Corporation announced that it has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of the Johannes Gutenberg University of Mainz, Germany.

SEATTLE II Supports Treatment of Acute PE With the Ekos EkoSonic System

March 30, 2014—Ekos Corporation (Bothell, WA), a BTG International group company, announced that the results of the SEATTLE II trial were presented at ACC.14: the 63rd annual scientific session of the American College of Cardiology in Washington, DC.